Hemophagocytic lymphohistiocytosis

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

4 regimens on this page 4 variants on this page

Untreated

HLH-94

back to top

Regimen

Study	Evidence
Henter et al. 1997	Non-randomized

Initial therapy

• Dexamethasone (Decadron) in a tapering schedule as follows:
  • 10 mg/m2/day (single or split doses not specified) for weeks 1 & 2
  • 5 mg/m2/day (single or split doses not specified) for weeks 3 & 4
  • 2.5 mg/m2/day (single or split doses not specified) for weeks 5 & 6
  • 1.25 mg/m2/day (single or split doses not specified) for week 7
  • Taper off during week 8 (exact schedule not specified)
• Etoposide (Vepesid) 150 mg/m² IV as follows:
  • Twice per week for weeks 1 & 2
  • Once per week for weeks 3 to 8
• Methotrexate (MTX) (dose not specified) IT once per week for weeks 3 to 6 in patients "with progressive neurological symptoms and/or persisting abnormal cerebrospinal fluid findings."

Supportive medications

• Prophylactic cotrimoxazole (5 mg/kg of trimethoprim equivalent), three times weekly
• An oral antimycotic during initial dexamethasone phase

8-week course; patients without familial or persistent disease then stopped. Patients with familial, persistent, or relapsed disease were treated with up to one year of continuation therapy, until an allogeneic HCT could be performed, as follows:

Continuation therapy

• Dexamethasone (Decadron) 10 mg/m2/day for three days, every two weeks (even weeks)
• Etoposide (Vepesid) 150 mg/m² IV once every two weeks (odd weeks)
• Cyclosporine A aiming for trough blood levels of 200 μg/L (not clear from the paper whether this is modified or non-modified)

Continuous for up to 52 weeks

References

1. Henter JI, Aricò M, Egeler RM, Elinder G, Favara BE, Filipovich AH, Gadner H, Imashuku S, Janka-Schaub G, Komp D, Ladisch S, Webb D. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol. 1997 May;28(5):342-7. link to original article does not contain protocol PubMed
   1. Update: Henter JI, Samuelsson-Horne A, Aricò M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G; Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002 Oct 1;100(7):2367-73. link to original article contains verified protocol PubMed
   2. Update: Trottestam H, Horne A, Aricò M, Egeler RM, Filipovich AH, Gadner H, Imashuku S, Ladisch S, Webb D, Janka G, Henter JI; Histiocyte Society. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011 Oct 27;118(17):4577-84. Epub 2011 Sep 6. link to original article contains verified protocol link to PMC article PubMed

Relapsed/Refractory

DEP

back to top

DEP: Doxil (Liposomal doxorubicin), Etoposide, MethylPrednisolone

Regimen

Study	Evidence	ORR
Wang et al. 2015	Phase II	76%

Note: Liposomal doxorubicin could be repeated, although details are scant in the text. End of etoposide is also somewhat unclear.

Chemotherapy

• Doxorubicin liposomal (Doxil) 25 mg/m² IV once on day 1
• Etoposide (Vepesid) 100 mg/m² IV once per week
• Methylprednisolone (Solumedrol) as follows:
  • Days 1 to 3: 15 mg/kg/day
  • Days 4 to 6: 2 mg/kg/day
  • Days 7 to 10: 1 mg/kg/day
  • Days 11 to 14: 0.75 mg/kg/day
  • Days 15 to 21: 0.5 mg/kg/day
  • Days 22 to 28: 0.4 mg/kg/day
  • Days 29 to 35: 0.3 mg/kg/day
  • Days 36 to 42: 0.2 mg/kg/day
  • Days 43 to 49: 0.1 mg/kg/day

One course

References

1. Wang Y, Huang W, Hu L, Cen X, Li L, Wang J, Shen J, Wei N, Wang Z. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015 Nov 5;126(19):2186-92. Epub 2015 Aug 19. link to original article contains verified protocol link to PMC article PubMed